Nectar Lifesciences Ltd (NECLIFE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Nectar Lifesciences Ltd on NSE and BSE, with an AI summary of each filing.
Please find attached herewith copy of minutes of 31st AGM of the Company.
Annual General Meeting · 05 Oct 2026, 4:45 pm
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 03 Oct 2026, 9:44 pm
Nectar Lifesciences Faces GST Litigation Remand Involving ₹95.56 Crore Total Tax Demand The High Court of Punjab and Haryana, vide order dated 24th Sep'26, remanded a GST litigation matter involving Nectar Lifesciences back to the Commissioner (Appeals) for fresh consideration following a writ petition by tax authorities. The Appellate Authority had earlier dropped a tax demand of ₹89.32 crore plus interest and penalties, confirmed ₹17.06 lakh in ineligible ITC, and remanded ₹6.24 crore for adjudication. If reconsidered unfavorably, the company faces potential exposure of up to ₹95.56 crore plus applicable interest and penalties.
Please find attached herewith Revised Proceedings of 31st AGM
Annual General Meeting · 19 Sept 2026, 5:24 pm
Please find attached herewith outcome of Annual General Meeting held on September 18, 2026 with a copy Scrutinizer report and voting results.
Annual General Meeting · 18 Sept 2026, 10:54 pm
Please find attached herewith Proceedings of 31st AGM
Annual General Meeting · 18 Sept 2026, 5:55 pm
Please find attached herewith letter sent to the members pursuant to Regulation 36(1)(b)of the SEBI (LODR) Regulations, 2015.
Others (Uncategorized) · 22 Aug 2026, 8:02 pm
Nectar Lifesciences Announces 31st AGM and FY26 Annual Report Nectar Lifesciences (NECLIFE) will hold its 31st Annual General Meeting (AGM) virtually on 18th Sep'26 at 11:00 AM IST. The company has dispatched its FY26 Annual Report and AGM notice. Key dates include the e-voting period from 15th Sep'26 to 17th Sep'26 and a record date of 11th Sep'26. This communication fulfills Regulation 36(1)(b) by providing a web link to the annual report for shareholders who have not registered an email address, ensuring compliance and information dissemination ahead of the meeting.
Pursuant to Regulations 30 and 34 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith copy of Annual ....
Others (Uncategorized) · 20 Aug 2026, 5:11 pm
Please find attached herewith Notice of 31st AGM for the Financial Year 2025-26 is scheduled to be held on Friday, September 18, 2026
Annual General Meeting · 20 Aug 2026, 4:30 pm
Please find attached herewith letter of change in corporate office of the Company
Others (Uncategorized) · 15 Aug 2026, 5:09 pm
Nectar Lifesciences Announces Corporate Office Relocation in Chandigarh Nectar Lifesciences announced a change in its corporate office, as approved by the board on 14 Aug'26. Effective 15 Sep'26, the office will move to "Godrej Eternia," West Wing (Tower A), Plot No. 70, Industrial Area, Phase-1, Chandigarh, 160 002. The previous location was Plot No. 110 within the same industrial area. This corporate action is a logistical update with no immediate financial impact indicated.
We wish to inform you that the board of directors of Nectar Lifesciences Limited ('Company') in their meeting held on August 14, 2026, have, inter-alia, noted, decided and approved the ....
Outcome · 15 Aug 2026, 2:34 am
Please find attached herewith the financial results for the quarter ended on June 30, 2026.
Financial Result · 15 Aug 2026, 2:17 am
Nectar Lifesciences Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lacs) ■ Revenue: 44.2 (+6917.5% YoY | -65.7% QoQ) ■ EBITDA: -2,727 (-33569.0% YoY | +52.4% QoQ) ■ EBITDA Margin (%): -6,169 (-488300 bps YoY | -173082 bps QoQ) ■ PAT: -1,540 (+75.6% YoY | +77.3% QoQ) ■ EPS (INR): -0.79 (+72.0% YoY | +76.6% QoQ)
Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve the Unaudited Financial ....
Intimation · 14 Aug 2026, 5:30 am
Nectar Lifesciences Board Meeting Scheduled for Q1 FY'27 Results Nectar Lifesciences Ltd. has scheduled a Board of Directors meeting for Friday, 14 Aug'26. The primary agenda item is to consider and approve the Unaudited Financial Results for the first quarter ending on 30 Jun'26. The meeting will address this key financial disclosure along with other related matters. The announcement was made to the NSE (Symbol: NECLIFE) and BSE (Scrip Code: 532649) as per SEBI regulations.
Please find attached herewith letter of Resignation of Non-Executive Non-Independent Director of the Nectar Lifesciences Limited
Change in Management · 06 Aug 2026, 11:48 pm
Nectar Lifesciences: Non-Executive Director Resigns Dr. Surulichamy Senthilkumar has resigned as a Non-Executive Non-Independent Director of Nectar Lifesciences Ltd., effective from the close of business on 06 Aug'26. The resignation letter cites pre-occupations and other personal reasons for the departure. The company confirmed there are no other material reasons for the resignation beyond those stated. This change in board composition is a key governance update for the pharmaceutical company.
Please find attached herewith letter of Sale and Surrender of Leasehold Rights in Land Situated in Jammu
Others (Uncategorized) · 05 Aug 2026, 5:10 am
Nectar Lifesciences Sells Non-Core Assets in Jammu for INR 11.22 Crore Nectar Lifesciences sold its non-core, inoperative Narbada Industries unit on 04 Aug'26 for a total of INR 11.22 crore. The transaction includes INR 9.60 crore for leasehold rights and INR 1.62 crore for plant & machinery. The divested unit had zero revenue in FY26 and constituted 0.37% of the company's net worth as of 31 Mar'26. The buyer, Shree Balaji Cold Chain & Storage Services, is not a related party, ensuring the transaction is at arm's length.
Please find attached herewith letter w.r.t.: Update on Slump Sale
Others (Uncategorized) · 23 Jul 2026, 10:39 pm
Nectar Lifesciences Extends Slump Sale Completion Date for Capsule Business Nectar Lifesciences Ltd. and Capnest Health Care Private Limited have mutually agreed to extend the completion date for the slump sale of Nectar's Empty Hard Gelatin Capsule business. The new expected completion date is now on or before Dec 31, '26. The company stated that all other terms and disclosures related to the sale, as previously detailed in the letter dated Dec 20, '25, remain unchanged. This extension delays the finalization of the business transfer previously announced.
We wish to inform you that the board of directors of Nectar Lifesciences Limited (''Company'') has change the registered office of the Company
Others (Uncategorized) · 12 Jul 2026, 2:07 am
Nectar Lifesciences Announces Change of Registered Office Nectar Lifesciences (NECLIFE) has announced a change in its registered office effective from 15 Jul'26. The new office is located at Showroom no. 8, First Floor, Patiala Complex, Barwala Road, Dera Bassi, Punjab- 140 507. This relocation is within the same city and state limits and will not impact the company's operations or statutory registrations.
Financial Results for the Year 2025-26
Financial Result · 30 May 2026, 8:25 pm
Nectar Lifesciences Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 129 (+20701.6% YoY) ■ EBITDA: -5,724 (-142277.1% YoY | -2873.7% QoQ) ■ EBITDA Margin (%): -4,438 (-378951 bps YoY) ■ PAT: -6,792 (+47.8% YoY | Profit to Loss QoQ) ■ EPS (INR): -3.38 (+41.7% YoY | Profit to Loss QoQ)
Nectar Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the Audited Financial Results ....
Intimation · 30 May 2026, 5:30 am
Nectar Lifesciences to Approve FY26 Financial Results on May 30, 2026 Nectar Lifesciences Ltd. has scheduled a Board of Directors meeting on Sat, May 30, '26. The agenda includes the consideration and approval of the Audited Financial Results and Financial Statements for the financial year 2025-26. The meeting will address these key financial approvals along with other related matters as per SEBI regulations.
Please find attached herewith letter w.r.t.: Update on Slump Sale
Others (Uncategorized) · 28 Apr 2026, 9:59 pm
Nectar Lifesciences Extends Slump Sale Completion Date Nectar Lifesciences announced an extension for the slump sale of its Empty Hard Gelatin Capsule business to Capnest Health Care Private Limited. The expected completion date has been mutually extended to on or before 31 Jul'26. This update, dated 28 Apr'26, refers to the original disclosure from 20 Dec'25. All other terms and conditions of the slump sale as previously disclosed remain unchanged. This delay pushes back the timeline for the strategic divestment and associated cash inflows for Nectar.
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 28 Apr 2026, 6:50 pm
Nectar Lifesciences Receives Favourable Income Tax Order for AY 2017-18 Nectar Lifesciences received a favourable order on Apr 09, '26, from the Deputy Commissioner of Income Tax regarding Assessment Year 2017-18. This resolves a litigation previously initiated under the Income Tax Act. The order, which fully concludes the matter, carries no financial implication or claims against the company. This follows earlier favourable High Court orders from May '25 for Assessment Years 2018-19 to 2021-22, which allowed the company's writ petitions and led to the current resolution for AY 2017-18.
Please find attachment.
Others (Uncategorized) · 08 Apr 2026, 6:50 pm
Nectar Lifesciences Launches 100-Day Shareholder Outreach Campaign Nectar Lifesciences (NSE: NECLIFE) has launched its second 100-day "Saksham Niveshak" campaign, running from 01 Apr'26 to 09 Jul'26. This initiative, guided by the IEPF Authority, urges shareholders to update their KYC details and claim unpaid dividends. The campaign aims to prevent the transfer of unclaimed dividends and corresponding shares to the IEPF Authority, which occurs after seven consecutive years. Unclaimed dividends for FY19 and FY20 are specifically highlighted. Prompt action is advised to safeguard investor entitlements.
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 24 Mar 2026, 7:04 pm
Nectar Lifesciences Faces Litigation from CGST Dept Challenging Favorable Order The Principal Commissioner of CGST, Ludhiana has filed a writ petition challenging a favorable order Nectar Lifesciences received on May 27, 2025. The original order had dropped a demand of ₹89.32 crore against the company. If the High Court rules against Nectar, it could be exposed to this ₹89.32 crore demand plus interest and penalties, along with a separate ₹6.24 crore demand. The company is strongly contesting the petition. A hearing is scheduled for Apr 28, 2026, with the final liability currently unascertainable.
Please find attached herewith Intimation of inter-corporate loan agreement with Avensis Exports Private Limited, a Wholly Owned Subsidiary of the Nectar Lifesciences Limited
Others (Uncategorized) · 12 Mar 2026, 10:29 pm
Nectar Lifesciences to Lend INR 100 Crore to Wholly-Owned Subsidiary Nectar Lifesciences has entered into an inter-corporate loan agreement to lend up to INR 100 crore to its wholly-owned subsidiary, Avensis Exports Private Limited. The unsecured loan, executed on 11 Mar'26, is for general corporate purposes. It carries a fixed tenure of 10 years with an interest rate of 12% per annum on a simple basis. The transaction is classified as a related-party transaction conducted at arm's length. This agreement does not grant Nectar any special rights over the subsidiary.
Please find attached herewith disclosures under Regulation 30 of the Securities and Exchange of Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015
Others (Uncategorized) · 07 Mar 2026, 7:37 pm
Nectar Lifesciences Litigation Update: Suit Disposed, No Financial Impact Nectar Lifesciences announced on 07 Mar'26 that a suit filed by Sanjay Chemicals India Private Limited has been disposed of by the Mumbai City Civil Commercial Court. The plaintiff sought recovery of a ₹43,30,914 principal amount plus interest and penalties. The court returned the plaint, citing a lack of jurisdiction, following Nectar's successful arguments. The company reports the suit is disposed of with no financial implication, liability, or further action required, marking a positive resolution to the litigation.
Update on Acquisition of 100% paid- up equity share capital of Avensis Exports Private Limited (CIN: U51109DL2007PTC169484)
Others (Uncategorized) · 06 Mar 2026, 9:27 pm
Nectar Lifesciences Acquires Avensis Exports, Making it a Wholly Owned Subsidiary Nectar Lifesciences (NECLIFE) concluded the acquisition of 100% of the paid-up equity share capital in Avensis Exports Private Limited (AEPL) on 06 Mar'26. The transaction was completed for a total cash consideration of INR 24,96,000, paid through normal banking channels. Effective immediately, AEPL has become a Wholly Owned Subsidiary of Nectar Lifesciences. This action follows the company's prior disclosure on 02 Mar'26.